FINANCIAL STATEMENTS 142 ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2007 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 18 TRADE AND OTHER PAYABLES 2007 2006 2005 $m $m $m Current liabilities Trade payables 3,497 3,482 3,161 Value added and payroll taxes and social security 434 280 263 Other payables 865 1,166 854 Accruals 2,172 1,367 1,143 6,968 6,295 5,421 Non-current liabilities Other payables 229 254 72 Included in other payables are amounts totalling $209m 2006 $241m, 2005 $180m to meet insurance obligations of the Groups insurance subsidiaries.
19 PROVISIONS FOR LIABILITIES AND CHARGES Employee Other Severance Environmental bene ts provisions Total $m $m $m $m $m At 1 January 2005 34 67 121 83 305 Charge for the year 33 17 32 20 102 Cash paid 1 16 20 37 Exchange and other movements 4 11 1 16 At 31 December 2005 62 68 122 102 354 Charge credit for the year 1 56 36 4 87 On acquisition of subsidiary 20 20 Cash paid 36 29 36 5 106 Exchange and other movements 6 13 18 11 At 31 December 2006 31 95 109 131 366 Charge for the year 620 48 4 58 730 Cash paid 25 32 23 25 105 Exchange and other movements 17 10 2 29 At 31 December 2007 643 111 100 166 1,020 2007 2006 2005 $m $m $m Due within one year 387 39 45 Due after more than one year 633 327 309 1,020 366 354 AstraZeneca is undergoing a worldwide restructuring initiative which involves rationalisation of the Global Supply Chain, European Sales and Marketing, Information Services and Business Support infrastructure and Research and Development.
Employee costs in connection with the initiatives are recognised in severance provisions.
This is a three-year programme expected to be substantially completed by the end of 2009.
Employee benefit provisions include the executive deferred bonus plan and other employee benefit provisions.
Further details are included in Note 26.
Details of environmental and litigation provisions are provided in Note 27.
No provision has been released or applied for any purpose other than that for which it was established.
